What if a formulation were possible that removed the need for cold chain distribution?

There is a significant need for shelf-stable vaccines that are simpler to store and distribute. Vaccines require cold chain distribution and to be stored in a refrigerator or freezer, but this makes it difficult to achieve equitable global access to vaccines that protect against infectious diseases.

Protection against respiratory diseases may be enhanced by mucosal immunization at the point of infection, and both intranasal and pulmonary administration have potential as non-invasive delivery routes for mucosal this form of immunization. A shelf-stable inhaled vaccine could then be created via a dry powder formulation approach, using spray drying to make the powder.

Get immediate access to this webinar by filling out the form on this page.

Featured in this webinar

The webinar will look at the formulation of vaccines with dry powder respiratory delivery in mind, and manufacturing considerations for dry powder inhaled vaccines. A case study will discuss a recent joint effort between AAHI and Lonza to advance a dry powder inhalable vaccine candidate for tuberculosis. Spray drying was used to manufacture intranasal dry powders of an ID93 antigen and GLA-SE adjuvant formulation. The physicochemical properties of the powder and its aerosol performance using intranasal dry powder inhaler devices were also evaluated.

Key learning objectives:

  • Explore the global need for shelf-stable vaccines for pandemic response, and neglected tropical diseases
  • Describe the formulation approach and critical quality attributes of a non-invasive dry powder vaccine for inhaled delivery
  • Understand the spray drying process considerations to achieve a dry powder inhaled vaccine
You may also be interested in:
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center